A novel prognostic score ( HAMP ) for head and neck cancer patients with single and multiple SBRT ‐treated lung metastases derived from retrospective analyses of survival outcome
Head & Neck · 2025
DOI: 10.1002/hed.27913 ↗Kurz gefasst
Fachartikel in der Zeitschrift Head & Neck, 2025. Verfasst von Samuel M Vorbach und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Medical University of Innsbruck, Innsbruck, Austria. Hauptthemen laut MEDLINE: Radiosurgery, Lung Neoplasms, Head and Neck Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
We report on the characterization and introduction of a novel prognostic score for patients undergoing stereotactic body radiotherapy (SBRT) for the treatment of single and multiple pulmonary metastases (PMs) derived from head and neck cancer (HNC).
Methods
In this retrospective study, we examined selected factors associated with progression‐free survival (PFS) and overall survival (OS) among 59 patients with HNC treated with SBRT for a total of 118 PMs, between 2009 and 2023. Factors related to survival were included in the prognostic scoring system.
Results
Prognostic factors including histology, age, number of metastases, and performance status at first SBRT were weighted differently depending on the strength of correlation to PFS and OS. Total prognostic scores (HAMP) ranged from 13 to 24 points, with a cut‐off total score of ≤18 scoring points for patients in a high‐risk (HR) subcohort, and of ≥19 scoring points for patients in a low‐risk group (LR). Median PFS (23.8 vs. 5.5 months, p < 0.001) and OS (61.3 vs. 16.4 months, p < 0.001) were significantly longer in the low‐risk group compared to the high‐risk group.
Conclusion
The HAMP score might be a convenient tool to facilitate individualized treatment decisions and appropriate follow‐up. The accuracy and reliability of the score requires further evaluation in prospective studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Medical University of Innsbruck, Innsbruck, Austria.
- Department of Psychiatry, Psychotherapy, Psychosomatics and Medical Psychology, University Hospital of Psychiatry II, Medical University of Innsbruck, Innsbruck, Austria.
- Department of Otorhinolaryngology - Head and Neck Surgery, Medical University of Innsbruck, Innsbruck, Austria.
ORCID-Profile: Samuel M Vorbach, Manuel P Sarcletti, Julian Mangesius, Daniel Dejaco
Zitieren
APA
Vorbach, S. M., Seppi, T., Sarcletti, M. P., Kollotzek, S., Mangesius, J., Lehmann, J., Riedl, D., Pointner, M. J., Santer, M., Dejaco, D., Nevinny-Stickel, M., & Ganswindt, U. (2025). A novel prognostic score ( HAMP ) for head and neck cancer patients with single and multiple SBRT ‐treated lung metastases derived from retrospective analyses of survival outcome. Head & Neck. https://doi.org/10.1002/hed.27913
Vancouver
Vorbach SM, Seppi T, Sarcletti MP, Kollotzek S, Mangesius J, Lehmann J, et al. A novel prognostic score ( HAMP ) for head and neck cancer patients with single and multiple SBRT ‐treated lung metastases derived from retrospective analyses of survival outcome. Head & Neck. 2025. doi:10.1002/hed.27913
BibTeX
@article{Vorbach2025,
author = {Vorbach, Samuel M and Seppi, Thomas and Sarcletti, Manuel P and Kollotzek, Siegfried and Mangesius, Julian and Lehmann, Jens and Riedl, David and Pointner, Martin J and Santer, Matthias and Dejaco, Daniel and Nevinny-Stickel, Meinhard and Ganswindt, Ute},
title = {A novel prognostic score ( HAMP ) for head and neck cancer patients with single and multiple SBRT ‐treated lung metastases derived from retrospective analyses of survival outcome},
journal = {Head & Neck},
year = {2025},
doi = {10.1002/hed.27913}
}
EUVIMED